Research with Impact-Dr. Peter Ellis

  • January 11, 2016
  • News

A series of articles has been created by HHS Research which shine the spotlight on studies published in 2014 with an HHS Researcher as lead author. Each piece features a study published in a journal with an Impact Factor greater than 10 and provides information about the author and about the research they lead. If their work strikes a cord with you, Tweet us at @HamHealthSc and include hashtag: HHSResearch

Dr. Peter Ellis received his MBBS, MMED and PhD from the Sydney University. Dr. Ellis is currently a Professor at McMaster University in the Department of Oncology and is Division Head of Medical Oncology. Dr. Ellis’ areas of interest include patient attitudes towards randomized clinical trials, evaluating health outcomes, and doctor-patient communication, including the involvement of patients in decision-making, assessing patient understanding of and preferences for prognostic information, and evaluating the impact of patient use of the internet on the doctor-patient interaction

Peter Ellis PhotoPublication:

Ellis, P. (2014). Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): A Double – Blind, Randomised, Phase 3 Trial. Lancet, 15(12), 1379-1388.

Background on the study: Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical and clinical evidence of activity in non-small-cell lung cancer. BR.26 was designed to assess whether dacomitinib improved overall survival in heavily pretreated patients with this disease.

Conclusion: Dacomitinib did not increase overall survival and cannot be recommended for treatment of patients with advanced non-small-cell lung cancer previously treated with chemotherapy and an EGFR tyrosine-kinase inhibitor.